Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
sickle cell disease
Biotech
Pfizer axes phase 3 sickle cell study, cites recruitment issues
Pfizer has terminated one of two phase 3 trials assessing a monoclonal antibody designed to treat sickle cell disease.
Gabrielle Masson
Mar 26, 2024 5:31pm
ASH: Editas shares data for mid-stage sickle cell disease asset
Dec 11, 2023 2:33pm
ASH: Pfizer swims in crowded sickle cell, hemophilia waters
Dec 9, 2023 7:00pm
Graphite founder sets up new biotech to save sickle cell program
Dec 8, 2023 10:33am
CRISPR Therapeutics laid off staff a week after positive AdComm
Nov 22, 2023 1:36pm
Sickle cell gene therapy process may cause cancerous mutations
Nov 20, 2023 9:10am